The Future of Pharmacological Therapy for Risk Factor Reduction
- 1 January 1988
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 36 (Supplement) , 115-120
- https://doi.org/10.2165/00003495-198800363-00024
Abstract
The European Atherosclerosis Society has produced guidelines for the drug treatment of hyperlipidaemia. This, of necessity, is lifelong and therefore should be prescribed only after exclusion of...Keywords
This publication has 7 references indexed in Scilit:
- The recognition and management of hyperlipidaemia in adults: A policy statement of the European Atherosclerosis Society.1988
- Reduction of Mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by Combined Treatment with Clofibrate and Nicotinic AcidActa Medica Scandinavica, 1988
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987
- Strategies for the prevention of coronary heart disease: a policy statement of the European Atherosclerosis Society.1987
- SERUM CHOLESTEROL, BLOOD PRESSURE, AND MORTALITY: IMPLICATIONS FROM A COHORT OF 361 662 MENThe Lancet, 1986
- The Lipid Research Clinics Coronary Primary Prevention Trial ResultsJAMA, 1984
- A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.Heart, 1978